CPT1C and cancer: It is noteworthy that since the mediator of Mutp53-induced oncogenic events, CPT1C, is brain-specific, existing only in neurons while is overexpressed in a wide range of cancers (51), and a vast majority of small molecule drugs do not cross the blood-brain barrier (65), it is really promising to develop CPT1C inhibitors with maximal efficacy and minimal off-target effects.